Fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HepG2 cells and shows anti-diabetic effect in diabetic KKAy mice

Toxicology and Applied Pharmacology

Volumn 285, Issue 1, 2015, Pages 61-70

  Liu, Zhi Qin ^a   Liu, Ting ^a   Chen, Chuan ^a   Li, Ming Yan ^a   Wang, Zi Yu ^a   Chen, Ruo song ^a   Wei, Gui xiang ^a   Wang, Xiao yi ^a   Luo, Du Qiang ^a  

^a HEBEI UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Glucose uptake; Insulin resistance; Insulin signaling; Protein tyrosine phosphatase 1B

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; ENZYME INHIBITOR; FUMOSORINONE; GLUCOSE BLOOD LEVEL; HYDROXAMIC ACID; INSULIN; PROTEIN TYROSINE PHOSPHATASE 1B; PTPN1 PROTEIN, HUMAN; PTPN1 PROTEIN, MOUSE; PYRIDONE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; DIABETES MELLITUS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; HEPG2 CELL LINE; HUMAN; INSULIN RESISTANCE; LIVER; MALE; METABOLISM; MOUSE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HEP G2 CELLS; HUMANS; HYDROXAMIC ACIDS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; PYRIDONES; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84934271609     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.03.011     Document Type: Article

References (42)

1. Ahmad F., Azevedo J.L., Cortright R., Dohm G.L., Goldstein B.J. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J. Clin. Invest. 1997, 100:449-458.
2. Asante-Appiah K., Kennedy B.P. Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E663-E670.
3. Avruch J. Insulin signal transduction through protein kinase cascades. Mol. Cell. Biochem. 1998, 182:31-48.
4. Bertoni A.G., Hundley W.G., Massing M.W., Bonds D.E., Burke G.L., Goff D.C. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004, 27:699-703.
5. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M.B., Monauni T., Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity Studies in subjects with various degrees of glucose tolerance. Diabetes Care 2000, 23:57-63.
6. Byon J.C.H., Kusari A.B., Kusari J. Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol. Cell. Biochem. 1998, 182:101-108.
7. Cheung A., Kusari J., Jansen D., Bandyopadhyay D., Kusari A., Bryer-Ash M. Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus. J. Lab. Clin. Med. 1999, 134:115-123.
8. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
9. Cordero-Herrera I., Martín M.A., Bravo L., Goya L., Ramos S. Cocoa flavonoids improve insulin signalling and modulate glucose production via AKT and AMPK in HepG2 cells. Mol. Nutr. Food Res. 2013, 57:974-985.
10. de Koning E.J., Bonner-Weir S., Rabelink T.J. Preservation of beta-cell function by targeting beta-cell mass. Trends Pharmacol. Sci. 2008, 29:218-227.
11. Elchebly M., Payette P., Michaliszyn E., Cromlish W., Collins S., Loy A.L., Normandin D., Cheng A., Himms-Hagen J., Chan C.C., Ramachandran C., Gresser M.J., Tremblay M.L., Kennedy B.P. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999, 283:1544-1548.
12. Franke T.F., Yang S.I., Chan T.O., Datta K., Kazlauskas A., Morrison D.K., Kaplan D.R., Tsichlis P.N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995, 81:727-736.
13. Gum R.J., Gaede L.L., Koterski S.L., Heindel M., Clampit J.E., Zinker B.A., Trevillyan J.M., Ulrich R.G., Jirousek M.R., Rondinone C.M. Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 2003, 52:21-28.
14. Huijsduijnen R.H.V., Bombrun A., Swinnen D. Selecting protein tyrosine phosphatases as drug targets. Drug Discov. Today 2002, 7:1013-1019.
15. Jung D.W., Ha H.H., Zheng X., Chang Y.T., Williams D.R. Novel use of fluorescent glucose analogues to identify a new class of triazine-based insulin mimetics possessing useful secondary effects. Mol. BioSyst. 2011, 7:346-358.
16. Kandasamy N., Ashokkumar N. Protective effect of bioflavonoid myricetin enhances carbohydrate metabolic enzymes and insulin signaling molecules in streptozotocin-cadmium induced diabetic nephrotoxic rats. Toxicol. Appl. Pharmacol. 2014, 279:173-185.
17. Kenner K.A., Anyanwu E., Olefsky J.M., Kusari J. Protein-tyrosine phosphatase 1B Is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling. J. Biol. Chem. 1996, 271:19810-19816.
18. Klaman L.D., Boss O., Peroni O.D., Kim J.K., Martino J.L., Zabolotny J.M., Moghal N., Lubkin M., Kim Y.B., Sharpe A.H., Stricker-Krongrad A., Shulman G.I., Neel B.G., Kahn B.B. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. 2000, 20:5479-5489.
19. Klover P.J., Mooney R.A. Hepatocytes: critical for glucose homeostasis. Int. J. Biochem. Cell Biol. 2004, 36:753-758.
20. Leng Y., Karlsson H.K.R., Zierath J.R. Insulin signaling defects in type 2 diabetes. Rev. Endocr. Metab. Disord. 2004, 5:111-117.
21. Luo D.Q., Zhang J., Liu Z.Q. Protein tyrosine phosphatase inhibitor, preparation method and uses thereof [P] 2013, (PCT/CN2013/07523, Pub.No:WO/2013/174207, 2013-11-28).
22. Maeda A., Kai K., Ishii M., Ishii T., Akagawa M. Safranal, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves glucose tolerance in diabetic KK-Ay mice. Mol. Nutr. Food Res. 2014, 58:1177-1189.
23. Newsholme E.A., Dimitriacdis G. Integration of biochemical and physiologic effects of insulin on glucose metabolism. Exp. Clin. Endocrinol. Diabetes 2001, 109:122-134.
24. Panzhinskiy E., Ren J., Nair S. Pharmacological inhibition of protein tyrosine phosphatase 1B: A promising strategy for the treatment of obesity and type 2 diabetes mellitus. Curr. Med. Chem. 2013, 20:2609-2625.
25. Peng J., Huan Y., Jiang Q., Sun S.J., Jia C.M., Shen Z.F. Effects and potential mechanisms of pioglitazone on lipid metabolism in obese diabetic KKAy mice. PPAR Res. 2014, 538183. 10.1155/2014/538183.
26. Popov D. Novel protein tyrosine phosphatase 1B inhibitors: interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control. Biochem. Biophys. Res. Commun. 2011, 410:377-381.
27. Qin N., Li C.B., Jin M.N., Shi L.H., Duan H.Q., Niu W.Y. Synthesis and biological activity of novel tiliroside derivants. Eur. J. Med. Chem. 2011, 46:5189-5195.
28. Saltiel A.R., Pessin J.E. Insulin signaling pathways in time and space. Trends Cell Biol. 2002, 12:65-71.
29. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010, 87:4-14.
30. Shih Y.T., Chen P.S., Wu C.H., Tseng Y.T., Wu Y.C., Lo Y.C. Arecoline, a major alkaloid of the areca nut, causes neurotoxicity through enhancement of oxidative stress and suppression of the antioxidant protective system. Free Radic. Biol. Med. 2010, 49:1471-1479.
31. Shiuchi T., Cui T.X., Wu L., Nakagami H., Takeda-Matsubara Y., Iwai M., Horiuchi M. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 2002, 40:329-334.
32. Stull A.J., Wang Z.Q., Zhang X.H., Yu Y., Johnson W.D., Cefalu W.T. Skeletal muscle protein tyrosinephosphatase 1B regulates insulin sensitivity in African Americans. Diabetes 2012, 61:1415-1422.
33. Suzuki Y., Hatanaka Y., Taira M., Shlmad F., Hashimoto N., Takayanagi M., Taylor S.I., Makino H., Yoshida S. Insulin resistance associated with decreased levels of insulin-receptor messenger ribonucleic acid evidence of a de novo mutation in the maternal allele. J. Clin. Endocrinol. Metab. 1995, 80:1214-1220.
34. Tahrani A.A., Bailey C.J., Del Prato S., Barnett A.H. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011, 378:182-197.
35. Takada M., Sumi M., Maeda A., Watanabe F., Kamiya T., Ishii T., Nakano M., Akagawa M. Pyrroloquinoline quinone, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves impaired glucose tolerance in diabetic KK-A(y) mice. Biochem. Biophys. Res. Commun. 2012, 428:315-320.
36. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 46:733-749.
37. Tiganis T. PTP1B and TCPTP-nonredundant phosphatases in insulin signaling and glucose homeostasis. FEBS J. 2013, 280:445-458.
38. Whiteman E.L., Cho H., Birnbaum M.J. Role of Akt/protein kinase B in metabolism. Trends Endocrinol. Metab. 2002, 13:444-451.
39. White M.F. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol. Cell. Biochem. 1998, 182:3-11.
40. White M.F. IRS proteins and the common path to diabetes. Am. J. Physiol. Endocrinol. Metab. 2002, 283:E413-E422.
41. Xie W., Wang W., Su H., Xing D., Pan Y., Du L. Effect of ethanolic extracts of Ananas comosus L. leaves on insulin sensitivity in rats and HepG2. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 2006, 143:429-435.
42. Zabolotny J.M., Haj F.G., Kim Y.B., Kim H.J., Shulman G.I., Kim J.K., Neel B.G., Kahn B.B. Transgenic overexpression of proteintyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J. Biol. Chem. 2004, 279:24844-24851.